SGMO(SGMO)
SGMO
ANALYST COVERAGE13 analysts
HOLD
▲ +2464.1%upside to target
L $2.00
Med $4.00consensus
H $19.00Key MetricsTTM
Market Cap$64.63M
Revenue TTM—
Net Income TTM—
Free Cash Flow—
Gross Margin100.0%
Operating Margin-319.2%
Net Margin-356.9%
Return on Equity6686.4%
Return on Assets-205.7%
Debt / Equity—
Current Ratio0.70
EPS TTM—
PRICE
Prev Close
0.16
Open
0.14
Day Range0.14 – 0.16
0.14
0.16
52W Range0.10 – 0.77
0.10
0.77
8% of range
VOLUME & SIZE
Avg Volume
10.2M
FUNDAMENTALS
P/E Ratio
-0.4x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.54
High vol
TECHNICAL
RSI (14)
37
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 22
DEx-Dividend
In 90 days
Aug 19
PDividend Pay
In 96 days
Aug 25
SGMO News
About
for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Alexander Macrae
Website
Alexander D. Macrae Ch.B MRCPChief Executive Officer, President & Director
Gregory DavisHead of Research & Technology
Nathalie Dubois-StringfellowSenior Vice President & Chief Development Officer
David OjalaScientist II - Discovery & Translational Research
Nikunj JainInterim CFO and Principal Financial & Accounting Officer
Phillip RamseyChief Technical Officer
Scott WilloughbySenior Vice President, Chief Legal Officer & Corporate Secretary
Louise WilkieHead of Global Corporate Communications & Investor Relations
Stephanie J. SeilerVice President and Head of Business Development & Alliance Management